<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.340">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>pulmonary-circulation-disorders-</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
</style>


<script src="pulmonary-circulation-disorders-_files/libs/clipboard/clipboard.min.js"></script>
<script src="pulmonary-circulation-disorders-_files/libs/quarto-html/quarto.js"></script>
<script src="pulmonary-circulation-disorders-_files/libs/quarto-html/popper.min.js"></script>
<script src="pulmonary-circulation-disorders-_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="pulmonary-circulation-disorders-_files/libs/quarto-html/anchor.min.js"></script>
<link href="pulmonary-circulation-disorders-_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="pulmonary-circulation-disorders-_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="pulmonary-circulation-disorders-_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="pulmonary-circulation-disorders-_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="pulmonary-circulation-disorders-_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">



<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B10.jpg" class="img-fluid"></p>
<section id="pulmonary-circulation-disorders" class="level1">
<h1>Pulmonary Circulation Disorders</h1>
</section>
<section id="serdar-balci-md" class="level1">
<h1>Serdar BALCI, MD</h1>
</section>
<section id="pte-hemorrhage-infarction" class="level1">
<h1>PTE, HEMORRHAGE, INFARCTION</h1>
</section>
<section id="pulmonary-embolism" class="level1">
<h1>Pulmonary Embolism</h1>
<ul>
<li><strong>Blood clots occlude the large pulmonary arteries almost always embolic</strong></li>
<li><strong>&gt;95% of all pulmonary emboli arise from large deep veins of the lower legs</strong>
<ul>
<li><strong>popliteal vein and larger veins above it</strong></li>
</ul></li>
<li><strong>Can be small and clinically silent</strong></li>
<li><strong>Among hospitalized patients autopsy data 1-30%</strong>
<ul>
<li><strong>Severe burns, trauma, or fractures</strong></li>
</ul></li>
</ul>
</section>
<section id="venous-thrombosis-predisposing-factors" class="level1">
<h1>Venous thrombosis predisposing factors</h1>
<ul>
<li><strong>Prolonged bedrest</strong>
<ul>
<li><strong>With immobilization of the legs</strong></li>
</ul></li>
<li><strong>Surgery</strong>
<ul>
<li><strong>Orthopedic surgery, of knee and hip</strong></li>
</ul></li>
<li><strong>Severe trauma</strong>
<ul>
<li><strong>Burns, multiple fractures</strong></li>
</ul></li>
<li><strong>Congestive heart failure</strong></li>
<li><strong>In women, the period around parturition or oral contraception using birth control pills with high estrogen content</strong></li>
<li><strong>Disseminated cancer</strong></li>
<li><strong>Primary disorders of hypercoagulability</strong>
<ul>
<li><strong>Factor V Leiden</strong></li>
</ul></li>
</ul>
</section>
<section id="two-important-consequences-of-pte" class="level1">
<h1>Two important consequences of PTE</h1>
<ul>
<li><strong>Increase in pulmonary artery pressure</strong>
<ul>
<li><strong>From blockage of flow</strong></li>
<li><strong>Vasospasm caused by neurogenic mechanisms</strong></li>
<li><strong>Release of mediators</strong>
<ul>
<li><strong>Thromboxane A2, serotonin</strong></li>
</ul></li>
</ul></li>
<li><strong>ischemia of the downstream pulmonary parenchyma</strong></li>
</ul>
</section>
<section id="pulmonary-thromboembolism" class="level1">
<h1>Pulmonary Thromboembolism</h1>
<ul>
<li><strong>Sudden increase in pulmonary artery pressure</strong></li>
<li><strong>Diminished cardiac output</strong></li>
<li><strong>Right-sided heart failure</strong>
<ul>
<li><strong>Acute cor pulmonale</strong></li>
</ul></li>
<li><strong>Death</strong></li>
</ul>
</section>
<section id="hypoxemia-develops-in-pte" class="level1">
<h1>Hypoxemia develops in PTE</h1>
<ul>
<li><strong>Perfusion of lung zones that have become atelectatic</strong>
<ul>
<li><strong>Alveolar collapse occurs in the ischemic areas</strong></li>
<li><strong>Reduction in surfactant production</strong></li>
<li><strong>Pain leads to reduced movement of the chest wall</strong></li>
<li><strong>Pulmonary blood flow is redirected through areas of the lung that normally are hypoventilated</strong></li>
</ul></li>
<li><strong>Decrease in cardiac output</strong>
<ul>
<li><strong>Widening of the difference in arterial-venous oxygen saturation</strong></li>
</ul></li>
<li><strong>Right-to-left shunting of blood</strong>
<ul>
<li><strong>Patent foramen ovale, present in 30% of normal persons</strong></li>
</ul></li>
</ul>
</section>
<section id="ischemic-necrosis-in-pte" class="level1">
<h1>Ischemic necrosis in PTE</h1>
<ul>
<li><strong>Ischemic necrosis (infarction) occur in 10% in PTE</strong>
<ul>
<li><strong>compromise in cardiac function or bronchial circulation</strong></li>
<li><strong>that area is underventilated as a result of underlying pulmonary disease</strong></li>
</ul></li>
</ul>
<p><strong>saddle embolus at the main left and right pulmonary arteries</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B11.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B12.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="pte" class="level1">
<h1>PTE</h1>
<p><strong>60-80% of emboli are clinically silent</strong></p>
<p><strong>5% cause acute cor pulmonale, shock, or death</strong></p>
<p><strong>Pulmonary infarction</strong></p>
<ul>
<li><strong>Emboli usually resolve after the initial acute event</strong>
<ul>
<li><strong>Contract</strong></li>
<li><strong>Endogenous fibrinolytic activity</strong></li>
<li><strong>Total lysis of the thrombus</strong></li>
</ul></li>
<li><strong>Risk of recurrence is high</strong>
<ul>
<li><strong>30% chance of developing a second</strong></li>
</ul></li>
</ul>
</section>
<section id="infarction" class="level1">
<h1>Infarction</h1>
<ul>
<li><strong>Compromised cardiovascular status</strong>
<ul>
<li><strong>Congestive heart failure</strong></li>
</ul></li>
<li><strong>The more peripheral the embolic occlusion, the higher the risk of infarction</strong></li>
<li><strong>3/4 lower lobes</strong></li>
<li><strong>&gt;1/2 are multiple</strong></li>
<li><strong>Wedge-shaped</strong>
<ul>
<li><strong>Base at the pleural surface and the apex pointing toward the hilus</strong></li>
</ul></li>
</ul>
<p><strong>A small, roughly wedge-shaped hemorrhagic pulmonary infarct of recent occurrence</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B13.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B14.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="hemorrhagic-infarcts" class="level1">
<h1>Hemorrhagic infarcts</h1>
<p><strong>Lungs have dual circulation</strong></p>
<p><strong>Raised, red-blue areas in the early stages</strong></p>
<p><strong>Adjacent pleural surface covered by a fibrinous exudate</strong></p>
<p><strong>Occluded vessel is found near the apex of the infarcted area</strong></p>
<ul>
<li><strong>Red cells begin to lyse within 48 hours</strong></li>
<li><strong>Infarct pales</strong></li>
<li><strong>Red-brown</strong>
<ul>
<li><strong>Hemosiderin</strong></li>
</ul></li>
<li><strong>Fibrous replacement begins at the margins</strong>
<ul>
<li><strong>Gray-white peripheral zone</strong></li>
<li><strong>Converts the infarct into a scar</strong></li>
</ul></li>
<li><strong>Hallmark of fresh infarcts is coagulative necrosis of the lung parenchyma and hemorrhage</strong></li>
</ul>
</section>
<section id="nonthrombotic-forms-of-pulmonary-embolism" class="level1">
<h1>Nonthrombotic forms of pulmonary embolism</h1>
<ul>
<li><strong>Air, fat, and amniotic fluid embolism</strong></li>
<li><strong>Bone marrow embolism</strong>
<ul>
<li><strong>Massive trauma</strong></li>
<li><strong>Bone infarction secondary to sickle cell anemia</strong></li>
</ul></li>
<li><strong>Foreign body embolism</strong>
<ul>
<li><strong>Intravenous drug abuse</strong></li>
</ul></li>
<li><strong>Magnesium trisilicate (talc) → granulomatous response</strong></li>
</ul>
</section>
<section id="talc-granulomas" class="level1">
<h1>Talc Granulomas</h1>
<p><strong>Talc in interstitium → fibrosis</strong></p>
<p><strong>Talc in pulmonary arteries → Pulmonary hypertension</strong></p>
<p><strong>Talc crystals can be demonstrated by polarized light</strong></p>
</section>
<section id="pulmonary-hypertension" class="level1">
<h1>PULMONARY HYPERTENSION</h1>
</section>
<section id="pulmonary-hypertension-1" class="level1">
<h1>Pulmonary Hypertension</h1>
<p><strong>Mean pulmonary pressures reach one fourth or more of systemic levels</strong></p>
<p><strong>Most often secondary to a decrease in the cross-sectional area of the pulmonary vascular bed</strong></p>
<p><strong>Increased pulmonary vascular blood flow</strong></p>
</section>
<section id="secondary-pulmonary-hypertension" class="level1">
<h1>Secondary pulmonary hypertension</h1>
<ul>
<li><strong>Chronic obstructive or interstitial lung disease</strong>
<ul>
<li><strong>Destruction of lung parenchyma</strong></li>
<li><strong>Consequent reduction in alveolar capillaries</strong></li>
<li><strong>Increased pulmonary arterial resistance</strong></li>
<li><strong>Elevated arterial pressure</strong></li>
</ul></li>
<li><strong>Recurrent pulmonary emboli</strong>
<ul>
<li><strong>Reduction in the functional cross-sectional area</strong></li>
<li><strong>Increased vascular resistance</strong></li>
</ul></li>
<li><strong>Antecedent heart disease</strong>
<ul>
<li><strong>Mitral stenosis</strong></li>
<li><strong>Increases left atrial pressure</strong></li>
<li><strong>Higher pulmonary venous pressures</strong></li>
<li><strong>Pulmonary arterial hypertension</strong></li>
</ul></li>
<li><strong>Congenital left-to-right shunts</strong></li>
</ul>
</section>
<section id="primary-idiopathic-pulmonary-arterial-hypertension" class="level1">
<h1>Primary, idiopathic, pulmonary arterial hypertension</h1>
<p><strong>Most cases are sporadic</strong></p>
<p><strong>6% are familial with an autosomal dominant mode of inheritance</strong></p>
</section>
<section id="secondary-pulmonary-hypertension-1" class="level1">
<h1>Secondary pulmonary hypertension</h1>
<ul>
<li><strong>Endothelial cell dysfunction</strong>
<ul>
<li><strong>Due to the underlying disorder</strong></li>
<li><strong>Mechanical injury due to increased blood flow in left-to-right shunts</strong></li>
<li><strong>Biochemical injury produced by fibrin in recurrent thromboembolism</strong></li>
</ul></li>
<li><strong>Reduced production of vasodilatory agents</strong>
<ul>
<li><strong>Nitric oxide, prostacyclin</strong></li>
</ul></li>
<li><strong>Increasing synthesis of vasoconstrictive mediators</strong>
<ul>
<li><strong>Endothelin</strong></li>
</ul></li>
<li><strong>Production of growth factors and cytokines</strong>
<ul>
<li><strong>Induce the migration and replication of vascular smooth muscle</strong></li>
<li><strong>Elaboration of extracellular matrix</strong></li>
</ul></li>
</ul>
</section>
<section id="primary-pulmonary-hypertension" class="level1">
<h1>Primary pulmonary hypertension</h1>
<ul>
<li><strong>Uncommon familial form</strong></li>
<li><strong>TGF-β signaling pathway</strong>
<ul>
<li><strong>Key mediator of endothelial and smooth muscle dysfunction</strong></li>
<li><strong>Germline mutations of bone morphogenetic protein receptor type 2 (BMPR-2)</strong></li>
</ul></li>
<li><strong>The BMPR2 gene product</strong>
<ul>
<li><strong>a cell surface molecule that binds to a variety of TGF-β pathway ligands</strong></li>
<li><strong>inhibits proliferation</strong></li>
<li><strong>When mutated → abnormal vascular endothelial and pulmonary smooth muscle proliferation</strong></li>
</ul></li>
<li><strong>Possible role for the serotonin transporter gene (5HTT)</strong>
<ul>
<li><strong>Pulmonary smooth muscle cells increased proliferation on exposure to serotonin</strong></li>
</ul></li>
</ul>
</section>
<section id="vascular-alterations-in-all-forms-of-pulmonary-hypertension" class="level1">
<h1>Vascular alterations in all forms of pulmonary hypertension</h1>
<ul>
<li><strong>Involve the entire arterial tree</strong></li>
<li><strong>In the main elastic arteries</strong>
<ul>
<li><strong>Atheromas</strong></li>
</ul></li>
<li><strong>In medium-sized muscular arteries</strong>
<ul>
<li><strong>Proliferation of myointimal cells and smooth muscle cells</strong></li>
<li><strong>Cause thickening of the intima and media</strong></li>
<li><strong>Narrowing of the lumina</strong></li>
</ul></li>
<li><strong>In smaller arteries and arterioles</strong>
<ul>
<li><strong>Thickening, medial hypertrophy, and reduplication of the internal and external elastic membranes</strong></li>
</ul></li>
<li><strong>The wall thickness may exceed the diameter of the lumen</strong>
<ul>
<li><strong>Point of near-obliteration</strong></li>
</ul></li>
</ul>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B15.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B16.png" class="img-fluid"></p>
<p><strong>B: Marked medial hypertrophy.</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Idiopathic pulmonary arterial hypertension</strong></p>
<p><strong>Characteristic plexiform lesions</strong></p>
<p><strong>Endothelial proliferation forms multiple lumina within small arteries</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B17.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="pulmonary-hypertension-2" class="level1">
<h1>Pulmonary hypertension</h1>
<ul>
<li><strong>Secondary pulmonary hypertension may develop at any age</strong></li>
<li><strong>Primary pulmonary hypertension</strong>
<ul>
<li><strong>Young adults</strong></li>
<li><strong>More commonly women</strong></li>
<li><strong>Marked by fatigue, syncope (particularly on exercise), dyspnea on exertion, and sometimes chest pain</strong></li>
<li><strong>Severe respiratory insufficiency and cyanosis</strong></li>
<li><strong>Right-sided heart failure (decompensated cor pulmonale)</strong></li>
</ul></li>
</ul>
</section>
<section id="diffuse-alveolar-hemorrhage-syndromes" class="level1">
<h1>DIFFUSE ALVEOLAR HEMORRHAGE SYNDROMES</h1>
</section>
<section id="pulmonary-hemorrhage" class="level1">
<h1>Pulmonary hemorrhage</h1>
<ul>
<li><strong>Secondary causes of pulmonary hemorrhage</strong>
<ul>
<li><strong>Necrotizing bacterial pneumonia</strong></li>
<li><strong>Passive venous congestion</strong></li>
<li><strong>Bleeding diathesis</strong></li>
</ul></li>
<li><strong>Diffuse alveolar hemorrhage syndromes</strong>
<ul>
<li><strong>Primary</strong></li>
<li><strong>Immune-mediated diseases</strong></li>
<li><strong>Triad of hemoptysis, anemia, and diffuse pulmonary infiltrates</strong></li>
</ul></li>
</ul>
</section>
<section id="goodpasture-syndrome" class="level1">
<h1>Goodpasture Syndrome</h1>
<p><strong>Proliferative, rapidly progressive glomerulonephritis</strong></p>
<p><strong>Hemorrhagic interstitial pneumonitis</strong></p>
<p><strong>Antibodies targeted against the noncollagenous domain of the α3 chain of collagen IV</strong></p>
<p><strong>These antibodies can be detected in the serum of more than 90% of persons with Goodpasture syndrome</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B18.png" class="img-fluid"></p>
<ul>
<li><strong>Lungs are heavy</strong></li>
<li><strong>Red-brown consolidation</strong>
<ul>
<li><strong>Diffuse alveolar hemorrhage</strong></li>
</ul></li>
<li><strong>Focal necrosis of alveolar walls</strong></li>
<li><strong>Intra-alveolar hemorrhages</strong></li>
<li><strong>Fibrous thickening of the septa</strong></li>
<li><strong>Hypertrophic type II pneumocytes</strong></li>
<li><strong>Hemosiderin, both within macrophages and extracellularly</strong>
<ul>
<li><strong>Earlier episodes of hemorrhage</strong></li>
</ul></li>
<li><strong>Characteristic linear pattern of immunoglobulin deposition</strong>
<ul>
<li><strong>Usually IgG, sometimes IgA or IgM</strong></li>
<li><strong>Hallmark diagnostic finding in renal biopsy specimens</strong></li>
<li><strong>May be seen along the alveolar septa</strong></li>
</ul></li>
</ul>
<p><strong>Plasmapheresis</strong></p>
<p><strong>Immunosuppressive therapy</strong></p>
<p><strong>Renal transplantation</strong></p>
<p><strong>Diffuse alveolar hemorrhage syndrome</strong></p>
<p><strong>Large numbers of intra-alveolar hemosiderin-laden macrophages on a background of thickened fibrous septa</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B19.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPulmonary-Circulation-Disorderspptx-kopyas%C4%B110.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="idiopathic-pulmonary-hemosiderosis" class="level1">
<h1>Idiopathic Pulmonary Hemosiderosis</h1>
<ul>
<li><strong>Rare disease of uncertain etiology</strong></li>
<li><strong>Pulmonary manifestations and histologic features similar to those of Goodpasture syndrome</strong>
<ul>
<li><strong>No associated renal disease</strong></li>
<li><strong>No circulating anti-basement membrane antibody</strong></li>
</ul></li>
<li><strong>Most cases occur in children</strong>
<ul>
<li><strong>Reported in adults as well, who have a better prognosis</strong></li>
</ul></li>
<li><strong>Steroid and immunosuppressive therapy</strong>
<ul>
<li><strong>Survival has markedly improved from the historical 2.5 years</strong></li>
<li><strong>An immune-mediated etiology is postulated</strong></li>
</ul></li>
</ul>
</section>
<section id="pulmonary-angiitis-and-granulomatosis" class="level1">
<h1>Pulmonary Angiitis and Granulomatosis</h1>
<p><strong>Wegener Granulomatosis</strong></p>
<p><strong>80% develop upper respiratory or pulmonary manifestations</strong></p>
<p><strong>PR3-ANCAs are present in close to 95% of cases</strong></p>
<ul>
<li><strong>Lung lesions</strong></li>
<li><strong>Combination of necrotizing vasculitis</strong>
<ul>
<li><strong>Angiitis</strong></li>
</ul></li>
<li><strong>Parenchymal necrotizing granulomatous inflammation</strong></li>
<li><strong>Upper respiratory symptoms</strong>
<ul>
<li><strong>Chronic sinusitis, epistaxis, nasal perforation</strong></li>
</ul></li>
<li><strong>Pulmonary signs and symptoms</strong>
<ul>
<li><strong>Cough, hemoptysis, chest pain</strong></li>
</ul></li>
</ul>
</section>

</main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>